Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

Inclusion Criteria

• •Tissue diagnosis of lymphoplasmacytic lymphoma with surface immunoglobulin G (IgG), immunoglobulin A (IgA) or immunoglobulin M (IgM) phenotype with a monoclonal heavy and light chain as determined by flow cytometry; all primary diagnostic lymph node and/or bone marrow biopsies will be reviewed at the University of Texas M.D. Anderson Cancer Center (UTMDACC)
• •Previously untreated patients with lymphoplasmacytic lymphoma (of any subtype: IgG, IgA, IgM) in the asymptomatic phase
• •Patients must provide a lymph node sample of at least 1.5 cm in the long axis, or a bone marrow aspiration sample providing at least 5 million cluster of differentiation (CD)20 and/or CD38+ (approximately 10 ml)
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• •Serum creatinine =\< 1.5 mg/dl and a creatinine clearance \>= 30 ml/min
• •Total bilirubin =\< 1.5 mg/dl unless felt secondary to Gilbert's disease
• •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2 x upper limit of normal
• •Ability to provide informed consent, and to return to clinic for adequate follow-up for the period that the protocol requires
• •Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for 30 days after the last vaccination has been administered
• •Male subject agrees to use an acceptable method for contraception for the duration of the study